anvatabart opadotin

Anvatabart opadotin is an antibody-drug conjugate (ADC) designed for the treatment of various cancers, particularly those overexpressing human epidermal growth factor receptor 2 (HER2). It consists of anvatabart, a humanized anti-HER2 monoclonal antibody, site-specifically conjugated via a non-cleavable oxime linker to opadotin, a potent tubulin inhibitor (an MMAF analog also known as Amberstatin 269 or AS269). The antibody component targets and binds to HER2 on tumor cells, facilitating the internalization of the ADC. Once inside the cancer cell, the cytotoxic payload, opadotin, is released, which then inhibits tubulin polymerization, leading to G2/M phase cell cycle arrest and ultimately inducing apoptosis in the tumor cells. This targeted delivery mechanism aims to enhance efficacy while minimizing systemic toxicity. The drug was initially developed by Ambrx, Inc., which was later acquired by Johnson & Johnson.

Brand names

ARX788ARX-788ARX 788

Other names

Anvatabart opadotina